Viking Therapeutics is progressing well with its obesity drug pipeline, focusing on a unique dual agonist treatment in a competitive market dominated by Lilly and Novo Nordisk. The company targets capturing 5–10% of the market through global expansion and late-stage development, with Phase 3 trials for its oral drug VK2735 expected by late 2026. Commercial launch is anticipated in 2028, potentially generating $1.3 billion in sales by 2030. Despite concerns over cash burn, investor confidence remains strong, with consistent buying since April 2025 indicating optimism about the company's growth prospects.
Polaris Inc. reported a strong quarterly performance with earnings per share of $1.97, beating estimates by over 155%, and revenues of $2.02 billion, up 9.2% year-over-year. The growth was driven by sales recovery in the utility off-road vehicle segm...
Seagate Technology is set to report its Q2 2026 earnings with analysts expecting an EPS of $5.10 and revenue around $3.5 billion, reflecting strong demand for data storage driven by AI growth. The company's optimistic guidance aligns with these estim...
Teladoc Health, a leader in virtual healthcare services, has seen its average analyst price target rise from $8.35 to $11.00, reflecting increased confidence in its market position. The stock recently jumped 6.1% with high trading volume, driven by r...
Procter & Gamble, a leading consumer goods company and Dividend King, is seeing a decline in analyst price targets from $162.52 to $152 over the past year, though Deutsche Bank remains optimistic with a $177 target. Despite a strong history of beatin...
Cognizant Technology Solutions has seen a decline in analyst price targets from $74.94 to $56.33 over the past year, reflecting increased caution about its stock performance. Despite this, some analysts remain optimistic, with a notable price target ...
